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Recent advances in molecular pathology and targeted thera-
pies have opened a new era of personalized medicine for lung 
cancer treatment. Driver genetic alterations such as epidermal 
growth factor receptor (EGFR) mutations, as well as Kirsten rat 
sarcoma viral oncogene homolog (KRAS) and anaplastic lym-
phoma kinase (ALK) rearrangements, have been identified and 
are currently used as predictive biomarkers for targeted thera-
pies.1 Activating somatic mutations in the EGFR gene are known 
to be major driver mutations in that they exhibit a high inci-
dence in lung cancers and have played an important role in the 
development of targeted molecular therapies for lung cancer.2 
EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and 
erlotinib, are associated with anti-tumor activity, inhibiting 
multiple downstream signaling processes that activate cell pro-
liferation and other cell responses, including cell migration and 
angiogenesis.3 EGFR TKIs are approved in Korea as a first-line 
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treatment for advanced non-small cell lung cancer (NSCLC) 
with mutated EGFR (Fig. 1). In the Iressa Pan-Asia Study 
(IPASS) trial, tumors with mutated EGFR exhibited a 71.2% 
clinical response to first-line gefitinib treatment, while only 
1.1% of tumors with wild-type EGFR responded to the treat-
ment.4 Therefore, patient selection is critical for the clinical use 
of EGFR TKIs as a first-line treatment. Clinical characteristics 
such as female gender, never-smoker status, and Asian ethnicity 
were also found to be associated with the response to EGFR 
TKIs; however, the results of the IPASS study confirmed that 
molecular selection-based EGFR mutation testing is the stron-
gest predictive factor for EGFR TKI treatment response.4,5 
Thus, EGFR mutation testing is very important for lung 
cancer therapy. Likewise, rapid and accurate EGFR mutation 
testing is essential for proper patient selection when consider-
ing targeted therapy with EGFR TKIs. In addition, a standard 
set of guidelines suitable for the Korean medical community is 
necessary. In this article, we propose guideline recommenda-
tions for EGFR mutation testing that were discussed and ap-
proved by the Cardiopulmonary Pathology Study Group of the 
Korean Society of Pathologists (Table 1).
PATIENT SELECTION
The most important reason for EGFR mutation testing is to 
select patients who might benefit from EGFR TKI therapy. Pa-
tients that receive EGFR mutation testing are primarily those 
with advanced stage disease. EGFR mutations are more preva-
lent in female patients, never-smokers, and patients of Asian 
ethnicity. However, clinical features alone cannot entirely pre-
dict EGFR mutation status.6,7 Most of the guidelines published 
thus far recommend histologic type as the most important fac-
tor for determining whether EGFR mutational testing should 
be performed.8-10 Specifically, when patients are diagnosed with 
Fig. 1. Epidermal growth factor receptor (EGFR) tyrosine kinase in-
hibitors (TKIs) are approved as a first-line treatment for advanced 
non-small cell lung cancer harboring EGFR mutation.
Advanced non-small cell lung carcinoma
Positive
1st line: EGFR-TKI (e.g., gefitinib, erlotinib)
EGFR mutation testing
Table 1. Recommendation summary for EGFR mutation testing
Recommendation
Patient selection Pathologic diagnosis is the most important factor
Patients with non-small cell carcinoma, especially adenocarcinoma componenta
Other types if clinically indicated
Sample source Primary and metastatic sites are equally suitable
Biopsy (formalin-fixed paraffin-embedded tissue) and cytology specimens are equally suitable
Sample processing Routine preparation for tissue or cytology is suitable
Tumor content The presence of tumor cells must be verified by a pathologist
High percentage (ideally more than 50%) of tumor cells for direct sequencing
Lower percentage acceptable for methods with higher sensitivity 
Method for mutation testing Various methods can be used for mutation testing
New techniques must be approved by the Korean government
The pathologist should consider available facilities and the pros and cons of each method
Turnaround time The entire workflow process should be supervised by the pathologist
Pathologic diagnosis: 1-2 working days
Molecular diagnosis: 5-7 working days
Repeat examination The pathologist should consider repeating the examination under the following situations
Poor sequence data
Cycle threshold too close to the defined cut-off limit 
Result are not matched with previously well-defined clinical-pathologic characteristics
Reporting format Sample information, type of method, mutation status, comments
EGFR, epidermal growth factor receptor.
aIn this regard, poorly differentiated non-small cell carcinoma should be further classified into a more specific type whenever possible. A minimum immunohis-
tochemical panel (such as thyroid transcription factor 1/napsin A/p63 or p40) is recommended in small specimens to preserve as much tissue as possible for 
molecular testing. 
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NSCLC including an adenocarcinoma component or NSCLC-
not-otherwise-specified after immunohistochemistry, EGFR 
mutation testing is routinely recommended.9 Thus, patholo-
gists should try to further classify poorly differentiated NSCLC 
into more specific types, such as adenocarcinoma or squamous 
cell carcinoma, whenever possible (Fig. 2). In addition, to pre-
serve as much tissue as possible for molecular testing in small 
specimens, a minimum immunohistochemical panel such as 
thyroid transcription factor 1/napsin A/p63 or p40 is recom-
mended.9,11,12
EGFR mutations are detected in approximately 40% of Ko-
rean NSCLC patients with adenocarcinoma histology.13 Fur-
thermore, it has been reported that EGFR mutations are more 
prevalent in specific subtypes of adenocarcinomas such as lepid-
ic, papillary, or micropapillary, although it should be noted that 
these subtypes are not fully predictive of EGFR mutation sta-
tus.14,15 Although previous studies have reported that a small 
fraction of squamous cell carcinomas or small cell carcinomas 
harbor EGFR mutations,16-19 routine examination is not recom-
mended because the incidence in pure types is very low. How-
ever, in cases of female never-smokers, those with a combined 
tumor type, or when otherwise clinically indicated, mutation 
testing can be performed.
SAMPLE SOURCES
Various small biopsy and cytology specimens can be used as 
samples for mutation testing. More specifically, acceptable tis-
sue specimens include transbronchial biopsy, gun biopsy, com-
puted tomography-guided needle aspiration, endobronchial ul-
trasound-guided transbronchial needle aspiration, bronchial 
brushing/washing, and pleural fluid sampling.8,20,21 Many stud-
ies have shown that cytology specimens are suitable for assess-
ing EGFR mutations, and that the results are highly concor-
dant with those of corresponding histological specimens, espe-
cially when using more sensitive methods.20-24
There have been several reports on the heterogeneous distri-
bution of EGFR mutations and discordance of EGFR mutation 
status between primary tumors and corresponding metastatic 
tumors.25-27 In contrast, Yatabe et al.28 reported that a heteroge-
neous distribution of EGFR mutations is extremely rare in lung 
adenocarcinoma. Although there is an ongoing debate with re-
spect to these reports, and further studies are needed,29,30 sam-
ples from a small portion of primary or metastatic tumor can be 
used equally.
SAMPLE PROCESSING
Routinely prepared samples are mostly formalin-fixed, paraf-
fin-embedded (FFPE) tissues. Although there has been a report 
of fixation-related artifacts,31 routinely prepared FFPE tissues 
are the most practical and standard resource for EGFR muta-
tion analysis. There is consensus that 10% neutral-buffered for-
malin is the optimum fixative for preparing FFPE samples,8,31 
while the optimal fixation time ranges from 6 to 24 hours to 
avoid underfixation or overfixation, respectively.8,31 
Routinely prepared cytology specimens, such as alcohol-fixed 
smears or ThinPrep slides prepared by transferring cells in sus-
pension20,23 and cell block specimens,32 are also suitable materi-
als for EGFR mutation analysis.
ESTABLISHING ADEQUATE TUMOR CONTENT 
FOR MUTATION TESTING
Before mutation testing, the presence of tumor cells in the 
sample must be assessed by a pathologist. The ratio of tumor 
cells to normal cells is crucial for adequate mutation testing. 
For direct sequencing, the percentage of tumor cells in the sam-
ple should ideally be at least 50%, although reliable results can 
be influenced by a variety of factors. Thus, determination of the 
Sampling/Fixation/Processing
Histo-/Cytopathology
Molecular pathology
Poorly differentiated
1-2 working days
(more 1-2 days if 
IHC required)
5-7 working days
- Tumor content evaluation 
- Tumor dissection if required
- DNA extraction 
- Mutation testing
- Reporting  
Immmunohistochemistry
NSCLC
ADC SQC
SCLC
Favor ADC
NSCLC-NOS
Favor SQC
Fig. 2. Overall process for pathologic diagnosis and molecular 
analysis with recommended turnaround times. SCLC, small cell 
lung carcinoma; NSCLC, non-small cell lung carcinoma; ADC, ad-
enocarcinoma; SQC, squamous cell carcinoma; NSCLC-NOS, 
non-small cell carcinoma-not otherwise specified; IHC, immuno-
histochemistry.
http://www.koreanjpathol.orghttp://dx.doi.org/10.4132/KoreanJPathol.2013.47.2.100
Guideline for EGFR Mutation Testing • 103
percentage of tumor cells in a given tissue or cell specimen is 
recommended. Macro- or microdissection may be used to in-
crease the ratio of tumor to normal tissues if required. A study 
performed by Sun et al. showed that the following parameters 
correlate with the most reliable EGFR mutation results when 
using cytology samples: DNA concentration >25 µg/µL, con-
tent of >30 tumor cells, and tumor percentage >30%.23 The 
minimum number of tumor cells required for adequate testing 
and the minimum ratio of tumor to normal cells is influenced 
by the testing method (see below). 
METHODS FOR EGFR MUTATION TESTING
Various methods can be used for detecting EGFR muta-
tions.33-35 Pathologists should consider the available facilities 
and the pros and cons of each method, including the sensitivity 
and turnaround time. In addition, new techniques must be ap-
proved by the Korean government. 
Direct sequencing is considered to be the gold standard for 
EGFR mutation analysis. In Korea, most pathology laboratories 
perform direct sequencing for the detection of EGFR mutations 
using FFPE tissue samples. However, for directing DNA se-
quencing, a high ratio of tumor tissue to normal tissue content 
is required (more than 50% tumor content). In contrast, real 
time polymerase chain reaction (PCR)-based methods exhibit 
high sensitivity, requiring a mutant DNA content of only 1%.33 
However, these methods can only detect previously known mu-
tations or targeted sites. The peptide nucleic acid (PNA)-medi-
ated PCR clamping method was recently developed and ap-
proved in Korea. The PNA clamping method exhibits high 
sensitivity compared with direct sequencing, and clinical out-
comes are not significantly different between groups harboring 
EGFR mutations detected by direct sequencing or PNA-medi-
ated PCR clamping.36-38 Highly sensitive methods can also be 
useful for detection of EGFR mutations associated with acquir-
ed resistance, such as T790M.39 
TURNAROUND TIME
Gefitinib is approved as a first-line treatment for advanced 
NSCLC-harboring EGFR mutations. Thus, the results of muta-
tion analysis should be made available to physicians as soon as 
possible. Pathologic diagnosis and molecular testing are a com-
bined and continuous process and should be supervised by a pa-
thologist (Fig. 2). It is recommended that testing be completed 
within five to seven working days after ordering EGFR muta-
tion testing. 
Several factors may influence turnaround time. In general, 
pathologic diagnoses and EGFR mutation testing performed 
within the same department rather than at separate laboratories 
would have a shorter turnaround time. When mutation testing 
is performed by an outside laboratory, communication and co-
ordination between the pathology department and the external 
laboratory are encouraged.
REPEATED EXAMINATION
Several criteria for repeated examination of EGFR mutation 
status have been recommended. The test should be repeated in 
cases of poor sequencing data, a cycle threshold too close to the 
defined cut-off limit (with pyrosequencing or PNA clamp kit), 
and/or mutation results that are not matched with previously 
well-defined clinical-pathologic characteristics. Specifically, pa-
thologists should carefully interpret the results of EGFR muta-
tions found in heavy smokers, solid or mucinous cancer types, 
or when EGFR mutations are concurrent with other exclusive 
driver mutations.
REPORTING FORMAT
Molecular testing reports should contain the following infor-
mation: pathologic number, age, sex, hospital unit number, bi-
opsy site, sample source, requesting physician, requesting de-
partment, adequacy for testing (estimated tumor cell content), 
receipt day, report day, methodology used, exons tested and as-
sociated range of detectable mutations, mutation status, com-
ments, testing technician, and corresponding pathologist. 
PATHOLOGIST’S ROLES
The pathologist plays an essential role in EGFR mutation 
testing.40 The pathologist can either perform the test at the 
home institution or transfer the tissue to a reference laboratory 
for external examination. In both situations, the pathologist is 
responsible through the procedures. First, the pathologist should 
choose the most appropriate tissue to be tested.7,8,23 Second, the 
pathologist should verify that the selected tissue block for EGFR 
mutation testing contains sufficient tumor cells required for 
analysis. The proportion of the tumor cells in the tissue or cy-
tology samples is very important to prevent contamination 
with non-tumor cells.7,23 Lastly, the pathologist is responsible 
for accurate and prompt reporting, which should include results 
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from routing diagnostic information (such as histologic diagno-
sis), as well as from EGFR mutation testing. If the test is per-
formed by an external reference laboratory, the pathologist inte-
grates the test results into the pathology report of his/her insti-
tute.40 We recommend all patients with NSCLC having an ade-
nocarcinoma component or NSCLC-not-otherwise-specified af-
ter immunohistochemistry should be tested for EGFR muta-
tion. In the cases of squamous cell carcinomas or small cell car-
cinomas arising from never-smokers, mutation testing can be 
performed. As for the small biopsy or cytology specimens, mac-
ro- or microdissection may enhance mutation testing sensitivity. 
PERSPECTIVES AND ADDITIONAL 
RECOMMENDATIONS
EGFR mutations and ALK rearrangements are currently 
used as predictive biomarkers for targeted lung cancer therapy. 
In addition, other driver mutations are now receiving attention, 
including ROS1 rearrangement,41 BRAF mutation,42,43 HER2 
mutation,44 and RET rearrangement.45 In terms of molecular 
diagnostics, these other targetable mutations have developed 
the need for multiplex mutational testing. However, because 
most patients with lung cancer present with advanced-stage 
disease at the time of diagnosis, the diagnosis of lung cancer is 
often based on small specimens from a biopsy or cytology alone. 
Thus, each pathology department must develop a strategy to 
manage clinical samples and collaborate with clinicians.9 As 
mentioned above, these strategies include minimization of di-
agnostic stains in order to maximize the available tissue for mo-
lecular studies9,12 and reduction of the number of trimmings for 
slide sections. 
CONCLUSION
As targetable mutations are discovered and corresponding 
targeted agents are developed, molecular diagnostics using clin-
ical samples has become increasingly important. EGFR muta-
tions are the most robust predictive factors for response to EGFR 
TKIs. Thus, each pathology department should maintain an 
optimal organization for the entire workflow of EGFR muta-
tion testing, from sample collection to the final report. Lastly, 
pathologists should keep in mind that personalized medicine is 
driven by pathology and molecular diagnostics.
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